Tags

Type your tag names separated by a space and hit enter

Cannabinoids and psychosis.
Int Rev Psychiatry. 2009 Apr; 21(2):152-62.IR

Abstract

Recent advances in knowledge about cannabinoid receptor function have renewed interest in the association between cannabis and psychosis. Case series, autobiographical accounts, and surveys of cannabis users in the general population suggest an association between cannabis and psychosis. Cross-sectional studies document an association between cannabis use and psychotic symptoms, and longitudinal studies suggest that early exposure to cannabis confers a close to two-fold increase in the risk of developing schizophrenia. Pharmacological studies show that cannabinoids can induce a full range of transient positive, negative, and cognitive symptoms in healthy individuals that are similar to those seen in schizophrenia. There is considerable evidence that in individuals with an established psychotic disorder such as schizophrenia, exposure to cannabis can exacerbate symptoms, trigger relapse, and worsen the course of the illness. Only a very small proportion of the general population exposed to cannabis develop a psychotic illness. It is likely that cannabis exposure is a 'component cause' that interacts with other factors to 'cause' schizophrenia or other psychotic disorder, but is neither necessary nor sufficient to do so alone. Further work is necessary to identify the factors that underlie individual vulnerability to cannabinoid-related psychosis and to elucidate the biological mechanisms underlying this risk.

Authors+Show Affiliations

Psychiatry Service, VA Connecticut Healthcare System, West Haven, Connecticut 06516, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19367509

Citation

Sewell, R Andrew, et al. "Cannabinoids and Psychosis." International Review of Psychiatry (Abingdon, England), vol. 21, no. 2, 2009, pp. 152-62.
Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. Int Rev Psychiatry. 2009;21(2):152-62.
Sewell, R. A., Ranganathan, M., & D'Souza, D. C. (2009). Cannabinoids and psychosis. International Review of Psychiatry (Abingdon, England), 21(2), 152-62. https://doi.org/10.1080/09540260902782802
Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and Psychosis. Int Rev Psychiatry. 2009;21(2):152-62. PubMed PMID: 19367509.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoids and psychosis. AU - Sewell,R Andrew, AU - Ranganathan,Mohini, AU - D'Souza,Deepak Cyril, PY - 2009/4/16/entrez PY - 2009/4/16/pubmed PY - 2009/8/6/medline SP - 152 EP - 62 JF - International review of psychiatry (Abingdon, England) JO - Int Rev Psychiatry VL - 21 IS - 2 N2 - Recent advances in knowledge about cannabinoid receptor function have renewed interest in the association between cannabis and psychosis. Case series, autobiographical accounts, and surveys of cannabis users in the general population suggest an association between cannabis and psychosis. Cross-sectional studies document an association between cannabis use and psychotic symptoms, and longitudinal studies suggest that early exposure to cannabis confers a close to two-fold increase in the risk of developing schizophrenia. Pharmacological studies show that cannabinoids can induce a full range of transient positive, negative, and cognitive symptoms in healthy individuals that are similar to those seen in schizophrenia. There is considerable evidence that in individuals with an established psychotic disorder such as schizophrenia, exposure to cannabis can exacerbate symptoms, trigger relapse, and worsen the course of the illness. Only a very small proportion of the general population exposed to cannabis develop a psychotic illness. It is likely that cannabis exposure is a 'component cause' that interacts with other factors to 'cause' schizophrenia or other psychotic disorder, but is neither necessary nor sufficient to do so alone. Further work is necessary to identify the factors that underlie individual vulnerability to cannabinoid-related psychosis and to elucidate the biological mechanisms underlying this risk. SN - 1369-1627 UR - https://www.unboundmedicine.com/medline/citation/19367509/Cannabinoids_and_psychosis_ DB - PRIME DP - Unbound Medicine ER -